VistaGen Therapeutics, Inc. Stock Analysis & AI Score
VistaGen Therapeutics, Inc. (VTGN) has an ST Score of 39.6 (C), driven by its Forecast (A) and held back by its Profitability (F). Analysts rate it Hold with a $0.95 price target (+222.0% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
VistaGen Therapeutics, Inc. (VTGN) has an ST Score of 39.6 (C), driven by its Forecast (A) and held back by its Profitability (F). Analysts rate it Hold with a $0.95 price target (+222.0% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityF
All factor grades
- ForecastA
- GrowthB-
- ValuationC
- MomentumC-
- Financial StrengthD+
- ProfitabilityF
- Piotroski3/9
Contact
VTGN stock: frequently asked questions
What is VTGN's ST Score?
VistaGen Therapeutics, Inc. (VTGN) has an ST Score of 39.6 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is VTGN a buy, hold, or sell?
Analysts rate VTGN a Hold, with a price target of $0.95 (+222.0% vs the current price). Our ST Score grades it C (39.6/100). The ST Score is a data-driven signal, not a recommendation.
What are VTGN's factor grades?
Valuation C, Profitability F, Financial Strength D+, Momentum C-, Growth B-, Forecast A.
What is VTGN's valuation grade?
VistaGen Therapeutics, Inc. (VTGN) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is VTGN's growth grade?
VistaGen Therapeutics, Inc. (VTGN) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is VTGN's profitability grade?
VistaGen Therapeutics, Inc. (VTGN) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is VTGN's financial strength grade?
VistaGen Therapeutics, Inc. (VTGN) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for VTGN?
The average analyst price target for VistaGen Therapeutics, Inc. (VTGN) is $0.95 from 7 analysts, which is +222.0% versus the recent price of $0.29.
What is VTGN's Piotroski score?
VistaGen Therapeutics, Inc. (VTGN) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.